Clinical trials: HIV-1
HIV Infections
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
Although some doctors favor starting anti-HIV treatment as soon as possible after patients learn they are infected, it is not known if treatment for recently infected patients results in long-term benefits or harm.
- Trial name
- NCT00090779
- Testing
- Emtricitabine/ tenofovir disoproxil fumarate, Lopinavir/Ritonavir
- Where
- 27 sites in United States, Peru
- Volunteers
- 130 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections
A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed
This study is designed to assess the antiviral activity and safety of a two-drug regimen of CAB LA + RPV LA compared with maintenance of BIK. BIKTARVY is a registered trademark of Gilead Sciences.
- Trial name
- SOLAR (NCT04542070)
- Testing
- Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets
- Where
- 117 sites in United States, Australia and 12 more
- Volunteers
- 687 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
The hypothesis tested in this study is that doravirine (MK-1439) at the final dose selected is superior to efavirenz, each given in combination with TRUVADA®, as measured by the percentage of participants with CNS events by Week…
- Trial name
- NCT01632345
- Testing
- Doravirine, Efavirenz, TRUVADA®
- Volunteers
- 342 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1 Infection
HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women
Women sometimes develop cancer in an area called the cervix, which is the opening to the uterus, or womb. Women who have HIV are more likely to get this kind of cancer than women who do not have HIV.
- Trial name
- NCT01315353
- Testing
- Cervical Cryotherapy, Loop Electrosurgical Excision Procedure (LEEP)
- Where
- 13 sites in Botswana, Haiti and 5 more
- Volunteers
- 467 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV-1-infection
B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults
Atripla (ATP: FTC/TDF/EFV) was the first single pill treatment for HIV and was the most prescribed first-line treatment from approximately 2008 to 2013 for people infected with HIV.
- Trial name
- NCT03532425
- Testing
- B/F/TAF, Atripla
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- University of Alberta
HIV-1 Infection
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavimab (TAB; GS-5423) and zinlirvimab (ZAB; GS-2872)) with lenacapavir (LEN) in…
- Trial name
- NCT05729568
- Testing
- Teropavimab, Zinlirvimab, Lenacapavir Tablet
- Where
- 34 sites in United States, Australia and 2 more
- Volunteers
- 83 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus Genotype-1
A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1
The purpose of this study is to evaluate the safety and tolerability of TMC435 along with pegylated interferon alpha-2a (PegIFNα-2a) and ribavirin (RBV) triple therapy in hepatitis C virus genotype-1 infected subjects…
- Trial name
- NCT01479868
- Testing
- TMC435, Pegylated interferon alpha-2a, Ribavirin
- Where
- 32 sites in United States, Canada and 6 more
- Volunteers
- 109 people
- Sponsor
- Janssen R&D Ireland
HIV-1 Infection
Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
The objective of this study is to evaluate the safety and efficacy of a regimen containing cobicistat-boosted atazanavir (ATV+COBI) plus emtricitabine/tenofovir disoproxil fumarate (Truvada®; FTC/TDF) versus ritonavir-boosted…
- Trial name
- NCT00892437
- Testing
- COBI, RTV, ATV
- Where
- 31 sites in United States
- Volunteers
- 85 people
- Sponsor
- Gilead Sciences
HIV-1 Infection
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants
The primary objective of the study is to investigate the short-term antiviral potency of bictegravir at multiple doses in antiretroviral (ART) treatment-naive adult participants and participants who are ART-experienced but…
- Trial name
- NCT02275065
- Testing
- Bictegravir
- Where
- 16 sites in United States
- Volunteers
- 23 people
- Sponsor
- Gilead Sciences
HIV, HIV Pre-exposure Prophylaxis
Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)
This double-blind, placebo-controlled study was designed to assess the safety, tolerability, and pharmacokinetics of oral MK-8527 taken once monthly (QM) in participants at low risk for human immunodeficiency virus Type 1 (HIV-1)…
- Trial name
- NCT06045507
- Testing
- MK-8527
- Where
- 18 sites in United States, Israel and 1 more
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV-I, Human Immunodeficiency Virus Type 1
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
This study will evaluate whether oral islatravir (ISL) is effective in preventing Human Immunodeficiency Virus Type 1 (HIV-1) infection in women at high-risk for HIV-1 infection.
- Conditions
- HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis
- Trial name
- Impower-022 (NCT04644029)
- Testing
- Islatravir, FTC/TDF
- Where
- 24 sites in United States, South Africa and 1 more
- Volunteers
- 730 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1-infection
Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3
Protocol Title: DOLCE: Dolutegravir-Lamivudine for naïve HIV-Infected Patients with ≤200 CD4/mm3 Protocol Number: FH-57 Study Objectives: To assess the antiviral activity at week 48 of DTG+3TC among naïve HIV patients with a CD4…
- Trial name
- DOLCE (NCT04880395)
- Testing
- Intervention Arm: dolutegravir/lamivudine, Comparator ARM: TDF/XTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine)
- Where
- 11 sites in Argentina, Brazil
- Volunteers
- 265 people
- Sponsor
- Fundación Huésped
HIV, HIV Infections
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir…
- Trial name
- NCT01780506
- Testing
- E/C/F/TAF, E/C/F/TDF
- Where
- 117 sites in United States, Australia and 10 more
- Volunteers
- 872 people
- Sponsor
- Gilead Sciences
HIV Infections
Autologous Dendritic Cell Vaccine in HIV1 Infection
This study aims to look at the safety and tolerability of immunization with dendritic cell vaccine prepared using the patient's own cells and virus.
- Trial name
- NCT00510497
- Testing
- Autologous HIV-1 ApB DC Vaccine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sharon Riddler
HIV-1-infection
Group-Based Intervention to Improve Mental Health and Adherence Among Youth Living With HIV in Low Resource Settings
IMPAACT 2016 was a multi-site, two-arm, individually randomized, controlled study to evaluate whether an Indigenous Leader Outreach Model (ILOM) of trauma-informed cognitive behavioral therapy (TI-CBT) delivered by Indigenous…
- Trial name
- NCT04024488
- Testing
- Youth TI-CBT Intervention Arm, Youth Discussion Control Arm, Caregiver TI-CBT Intervention Arm
- Where
- 8 sites in Botswana, Malawi and 2 more
- Volunteers
- 484 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
HIV Infections
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are widely used as part of combination antiretroviral therapy (ART) for infants and children, but NNRTI resistance is increasing, leading to treatment failure.
- Trial name
- NCT01504841
- Testing
- Etravirine (ETR)
- Where
- 11 sites in United States, Brazil and 1 more
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1
Research Hypothesis: Administration of BMS-663068, a prodrug for HIV attachment inhibitor BMS-626529, will result in a mean decrease of at least 1 log10 in HIV RNA at Day 9 following 8 days of therapy in at least one dosing…
- Trial name
- NCT01009814
- Testing
- BMS-663068, Ritonavir
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- ViiV Healthcare
HIV-1
TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents
The purpose of this study is to determine the safety and antiviral activity of etravirine in treatment-experienced human immunodeficiency virus (HIV) infected children and adolescents.
- Trial name
- NCT00665847
- Testing
- Etravirine (TMC125), Optimized background regimen (OBR)
- Where
- 42 sites in United States, Argentina and 11 more
- Volunteers
- 103 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections, Health Volunteers
A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults
The purpose of the ABX464-005 study is to characterize the systemic and mucosal immunological sequelae associated with exposure to ABX464 and to explore selected immunological endpoints, compartmental pharmacokinetics, and…
- Trial name
- NCT02990325
- Testing
- ABX464 150mg, ABX464 50mg
- Where
- Spain
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Abivax S.A.
Acquired Immunodeficiency Syndrome, HIV Infections
Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents
The primary objectives of this study are to evaluate the steady-state pharmacokinetics (PK) and confirm the dose of the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) single-tablet regimen…
- Trial name
- NCT01721109
- Testing
- EVG/COBI/FTC/TDF
- Where
- 18 sites in United States, South Africa and 1 more
- Volunteers
- 50 people
- Sponsor
- Gilead Sciences